Key result
Cpc-PH exhibits ~2-fold higher bioactive lipid levels per SD versus Ipc-PH, largely shared with PAH.
Why the study?
Pulmonary hypertension due to left-sided heart disease includes subtypes with distinct clinical profiles and outcomes, and the molecular heterogeneity underlying these subtypes is unclear.
Does plasma bioactive lipid and oxylipin profiling differentiate combined pre- and postcapillary pulmonary hypertension (Cpc-PH) from isolated postcapillary pulmonary hypertension (Ipc-PH) and identify shared molecular pathways with pulmonary arterial hypertension (PAH)?
Cross-Sectional (n=128)
No
Does plasma bioactive lipid and oxylipin profiling differentiate combined pre- and postcapillary pulmonary hypertension (Cpc-PH) from isolated postcapillary pulmonary hypertension (Ipc-PH) and identify shared molecular pathways with pulmonary arterial hypertension (PAH)?
Answers are grounded in this paper and cite their sources.
Patients with Cpc-PH display a distinct plasma bioactive lipid signature (elevated PUFAs and FAHFAs, lower vasodilatory/pro-resolving oxylipins) that closely mirrors Group 1 PAH rather than Ipc-PH and correlates with mortality, supporting molecular subphenotyping and potential shared therapeutic targets.
BACKGROUND: Pulmonary hypertension (PH) due to left-sided heart disease (Group 2 PH) is the most common type of PH and comprises 2 subtypes with distinct clinical profiles and outcomes: isolated postcapillary PH and combined pre- and postcapillary PH (Cpc-PH). Bioactive lipid derivatives may underlie these divergent subphenotypes. This study aimed to investigate the molecular heterogeneity underlying Group 2 PH subtypes and identify shared pathways between Cpc-PH and pulmonary arterial hypertension (PAH). METHODS: In a cross-sectional study, we profiled plasma bioactive lipids using liquid chromatography-mass spectrometry in 128 patients with isolated postcapillary PH (n=21), Cpc-PH (n=69), or PAH (n=38), as well as in plasma samples from animal models of severe PH. Of those, 28 were higher in Cpc-PH, particularly those in the polyunsaturated fatty acid and fatty acyl esters of hydroxy fatty acid pathways. Notably, 24 of these 28 did not differ from PAH, indicating a PAH-like bioactive lipid signature. Several metabolites, including adrenic acid, linoleic acid, docosatrienoic acid, palmitoleic acid, and fatty acyl esters of hydroxy fatty acids, were associated with increased mortality. These findings were corroborated in the Su/Hx rat model of PAH, where a subset of Cpc-PH-elevated metabolites was similarly increased. CONCLUSIONS: Cpc-PH exhibits a distinct, PAH-like metabolomic signature characterized by higher polyunsaturated fatty acids and fatty acyl esters of hydroxy fatty acids and lower pro-resolvin/vasodilatory oxylipins compared with isolated postcapillary PH. These findings have implications for PH classification, may inform diagnostic strategies, and nominate lipid pathways for therapeutic targeting.
No takes yet. Share an insight, caveat, or question.
Alotaibi et al. (2026) conducted a cross-sectional in Pulmonary hypertension (Group 2 PH subtypes Ipc-PH and Cpc-PH, and Group 1 PAH) (n=128). Combined pre- and postcapillary pulmonary hypertension (Cpc-PH) and plasma bioactive lipid/oxylipin profiles vs. Isolated postcapillary pulmonary hypertension (Ipc-PH) and Group 1 pulmonary arterial hypertension (PAH) was evaluated on Differential plasma bioactive lipid metabolites (out of 844 assayed) between Cpc-PH and Ipc-PH (OR 2.05-3.37 per 1-SD log-analyte for 28 metabolites elevated in Cpc-PH, p=<0.05). Combined pre- and postcapillary PH exhibited 28 elevated bioactive lipid metabolites compared with isolated postcapillary PH, 24 of which were shared with PAH.
Synapse has enriched 10 related papers. Consider them for comparative context: